Business Relations Table - o4.fyi ()

Anmelden Gast|Guest
Beispiel: brt.php?search=wide&s=wide&p=adjective&o=wideness

Domain-Statistiken für "ibtrozi.com"

32
Business Relations
33
Eindeutige Domains
20
Gefundene Einträge
BR-Relations: 32
From Domain Role To Domain Path Aktionen
/lung-cancer/nsclc/biomarkers/ros1
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/patient-support/
/patient-resources/
/patient-resources/
/patient-resources/
/
/
/
/approved/ibtrozi/
/media-hub/onco360-has-been-selected-as-a-national-specialty-pharmacy-partner-for-ibtrozi-taletrectinib-manufactured-by-nuvation-bio-inc/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/
/jcn-newswire/eisai-and-nuvation-bio-enter-into-exclusive-licensing-agreement-for-taletrectinib-in-europe-and-additional-countries-outside-the-u-s-china-and-japan/